Literature DB >> 22935587

Workshop report from the National Institutes of Health Taskforce on the Research Needs of Eosinophil-Associated Diseases (TREAD).

Bruce S Bochner1, Wendy Book, William W Busse, Joseph Butterfield, Glenn T Furuta, Gerald J Gleich, Amy D Klion, James J Lee, Kristin M Leiferman, Michael Minnicozzi, Redwan Moqbel, Marc E Rothenberg, Lawrence B Schwartz, Hans-Uwe Simon, Michael E Wechsler, Peter F Weller.   

Abstract

BACKGROUND: Eosinophils are blood cells that are often found in high numbers in the tissues of allergic conditions and helminthic parasite infections. The pathophysiologic roles that eosinophils may serve in other human "eosinophil-associated" diseases remain obscure.
OBJECTIVE: National Institutes of Health (NIH) Institutes and the Office of Disease Prevention assembled an international taskforce of clinical and basic scientists with the charge to propose and prioritize unmet research needs in eosinophil-associated diseases.
METHODS: The taskforce used an organ system approach to identify the different and common themes of eosinophil cell involvement in these diseases. In early 2012, a draft document was circulated for review. The document was amended and the prioritizations were set at a NIH-organized workshop in June 2012.
RESULTS: The taskforce identified significant research needs. These needs cross disease entities but some are disease specific. There are substantial shortcomings to the various preclinical animal models, as well as significant gaps in our epidemiologic, pathophysiologic, diagnostic, prognostic, and therapeutic knowledge. The taskforce recognized that recent efforts by patient advocacy groups have played instrumental roles in improving the identification and characterization of these disorders. However, communications among the eosinophil-interested communities, for example, governmental funding and regulatory agencies, and industry and clinician scientists need to be more comprehensive.
CONCLUSIONS: Significant efforts are required to address our knowledge gaps to improve the outcomes of eosinophil-associated diseases. NIH Institutes, other federal agencies, lay organizations, and the pharmaceutical industry should consider the taskforce's recommendations in their future research activities.
Copyright © 2012 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22935587      PMCID: PMC3432981          DOI: 10.1016/j.jaci.2012.07.024

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  56 in total

Review 1.  Angiolymphoid hyperplasia with eosinophilia of the auricle: progression of histopathological changes.

Authors:  K G Effat
Journal:  J Laryngol Otol       Date:  2006-05       Impact factor: 1.469

2.  Reflections on eosinophils and flame figures: where there's smoke there's not necessarily Wells syndrome.

Authors:  Kristin M Leiferman; Margot S Peters
Journal:  Arch Dermatol       Date:  2006-09

Review 3.  Eosinophilic esophagitis: pathogenesis, genetics, and therapy.

Authors:  Carine Blanchard; Ning Wang; Marc E Rothenberg
Journal:  J Allergy Clin Immunol       Date:  2006-09-18       Impact factor: 10.793

4.  Eotaxin is required for the baseline level of tissue eosinophils.

Authors:  A N Matthews; D S Friend; N Zimmermann; M N Sarafi; A D Luster; E Pearlman; S E Wert; M E Rothenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

5.  Regulation of carcinogenesis by IL-5 and CCL11: a potential role for eosinophils in tumor immune surveillance.

Authors:  Ljubov Simson; Julia I Ellyard; Lindsay A Dent; Klaus I Matthaei; Marc E Rothenberg; Paul S Foster; Mark J Smyth; Christopher R Parish
Journal:  J Immunol       Date:  2007-04-01       Impact factor: 5.422

Review 6.  Eosinophilic esophagitis.

Authors:  Richard J Noel; Marc E Rothenberg
Journal:  Curr Opin Pediatr       Date:  2005-12       Impact factor: 2.856

7.  Eosinophilic fasciitis 30 years after - what do we really know? Report of 11 patients and review of the literature.

Authors:  Milos Antic; Stephan Lautenschlager; Peter H Itin
Journal:  Dermatology       Date:  2006       Impact factor: 5.366

8.  Cutting edge: human eosinophils regulate T cell subset selection through indoleamine 2,3-dioxygenase.

Authors:  Solomon O Odemuyiwa; Ahmad Ghahary; Yunyuan Li; Lakshmi Puttagunta; Joo Eun Lee; Sorin Musat-Marcu; Aziz Ghahary; Redwan Moqbel
Journal:  J Immunol       Date:  2004-11-15       Impact factor: 5.422

Review 9.  Idiopathic chronic eosinophilic pneumonia.

Authors:  Eric Marchand; Jean-François Cordier
Journal:  Semin Respir Crit Care Med       Date:  2006-04       Impact factor: 3.119

10.  Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients.

Authors:  L Guillevin; P Cohen; M Gayraud; F Lhote; B Jarrousse; P Casassus
Journal:  Medicine (Baltimore)       Date:  1999-01       Impact factor: 1.889

View more
  28 in total

1.  Dexpramipexole as an oral steroid-sparing agent in hypereosinophilic syndromes.

Authors:  Sandhya R Panch; Michael E Bozik; Thomas Brown; Michelle Makiya; Calman Prussin; Donald G Archibald; Gregory T Hebrank; Mary Sullivan; Xiaoping Sun; Lauren Wetzler; JeanAnne Ware; Michael P Fay; Cynthia E Dunbar; Steven I Dworetzky; Paneez Khoury; Irina Maric; Amy D Klion
Journal:  Blood       Date:  2018-05-08       Impact factor: 22.113

2.  Mice deficient in the St3gal3 gene product α2,3 sialyltransferase (ST3Gal-III) exhibit enhanced allergic eosinophilic airway inflammation.

Authors:  Takumi Kiwamoto; Mary E Brummet; Fan Wu; Mary G Motari; David F Smith; Ronald L Schnaar; Zhou Zhu; Bruce S Bochner
Journal:  J Allergy Clin Immunol       Date:  2013-07-02       Impact factor: 10.793

Review 3.  Biologic therapies targeting eosinophils: current status and future prospects.

Authors:  Fanny Legrand; Amy D Klion
Journal:  J Allergy Clin Immunol Pract       Date:  2015 Mar-Apr

4.  Siglec-8 antibody reduces eosinophils and mast cells in a transgenic mouse model of eosinophilic gastroenteritis.

Authors:  Bradford A Youngblood; Emily C Brock; John Leung; Rustom Falahati; Bruce S Bochner; Henrik S Rasmussen; Kathryn Peterson; Christopher Bebbington; Nenad Tomasevic
Journal:  JCI Insight       Date:  2019-10-03

Review 5.  The role of lung epithelial ligands for Siglec-8 and Siglec-F in eosinophilic inflammation.

Authors:  Takumi Kiwamoto; Toshihiko Katoh; Michael Tiemeyer; Bruce S Bochner
Journal:  Curr Opin Allergy Clin Immunol       Date:  2013-02

Review 6.  Activation states of blood eosinophils in asthma.

Authors:  M W Johansson
Journal:  Clin Exp Allergy       Date:  2014-04       Impact factor: 5.018

Review 7.  "Siglec"ting the allergic response for therapeutic targeting.

Authors:  Bruce S Bochner
Journal:  Glycobiology       Date:  2016-02-23       Impact factor: 4.313

8.  Long-Term Clinical Outcomes of High-Dose Mepolizumab Treatment for Hypereosinophilic Syndrome.

Authors:  Fei Li Kuang; Michael P Fay; JeanAnne Ware; Lauren Wetzler; Nicole Holland-Thomas; Thomas Brown; Hector Ortega; Jonathan Steinfeld; Paneez Khoury; Amy D Klion
Journal:  J Allergy Clin Immunol Pract       Date:  2018-05-08

9.  Genetic and epigenetic underpinnings of eosinophilic esophagitis.

Authors:  Joseph D Sherrill; Marc E Rothenberg
Journal:  Gastroenterol Clin North Am       Date:  2014-03-24       Impact factor: 3.806

10.  Macrophages and cardiac fibroblasts are the main producers of eotaxins and regulate eosinophil trafficking to the heart.

Authors:  Nicola L Diny; Xuezhou Hou; Jobert G Barin; Guobao Chen; Monica V Talor; Julie Schaub; Stuart D Russell; Karin Klingel; Noel R Rose; Daniela Čiháková
Journal:  Eur J Immunol       Date:  2016-10-25       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.